398 related articles for article (PubMed ID: 17641984)
61. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation.
Fagius J; Lundgren J; Oberg G
Mult Scler; 2009 Feb; 15(2):229-37. PubMed ID: 18805841
[TBL] [Abstract][Full Text] [Related]
62. Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis.
Habek M; Barun B; Puretić Z; Brinar VV
Ther Apher Dial; 2010 Jun; 14(3):298-302. PubMed ID: 20609182
[TBL] [Abstract][Full Text] [Related]
63. [Evoked potentials with intrathecal and systemic corticosteroid therapy in multiple sclerosis].
Heun R; Emser W; Schimrigk K
EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1989 Jun; 20(2):88-91. PubMed ID: 2503359
[TBL] [Abstract][Full Text] [Related]
64. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain.
Casado V; Romero L; Gubieras L; Alonso L; Moral E; Martinez-Yelamos S; Martinez-Yelamos A; Carmona O; Arbizu T
Mult Scler; 2007 Jul; 13(6):800-4. PubMed ID: 17613609
[TBL] [Abstract][Full Text] [Related]
65. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
Roxburgh RH; Seaman SR; Masterman T; Hensiek AE; Sawcer SJ; Vukusic S; Achiti I; Confavreux C; Coustans M; le Page E; Edan G; McDonnell GV; Hawkins S; Trojano M; Liguori M; Cocco E; Marrosu MG; Tesser F; Leone MA; Weber A; Zipp F; Miterski B; Epplen JT; Oturai A; Sørensen PS; Celius EG; Lara NT; Montalban X; Villoslada P; Silva AM; Marta M; Leite I; Dubois B; Rubio J; Butzkueven H; Kilpatrick T; Mycko MP; Selmaj KW; Rio ME; Sá M; Salemi G; Savettieri G; Hillert J; Compston DA
Neurology; 2005 Apr; 64(7):1144-51. PubMed ID: 15824338
[TBL] [Abstract][Full Text] [Related]
66. A clinical longitudinal study of multiple sclerosis in Cantabria, Spain.
Morís G; Berciano J; Miró J
Neurologia; 2003 Dec; 18(10):723-30. PubMed ID: 14648348
[TBL] [Abstract][Full Text] [Related]
67. [Effect of methylprednisolone on the attention in patients with multiple sclerosis].
Kułakowska A; Halicka D; Drozdowski W; Braszko JJ
Pol Merkur Lekarski; 2006 Jan; 20(115):65-8. PubMed ID: 16617739
[TBL] [Abstract][Full Text] [Related]
68. Correlation of myelin basic protein-like material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment.
Whitaker JN; Layton BA; Herman PK; Kachelhofer RD; Burgard S; Bartolucci AA
Ann Neurol; 1993 Jan; 33(1):10-7. PubMed ID: 7684211
[TBL] [Abstract][Full Text] [Related]
69. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
70. Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone.
Danowski A; Magder L; Petri M
J Rheumatol; 2006 Jan; 33(1):57-60. PubMed ID: 16395750
[TBL] [Abstract][Full Text] [Related]
71. Self-rated physical health predicts change in disability in multiple sclerosis.
Drulovic J; Riise T; Nortvedt M; Pekmezovic T; Manigoda M
Mult Scler; 2008 Aug; 14(7):999-1002. PubMed ID: 18505776
[TBL] [Abstract][Full Text] [Related]
72. Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study.
Gray O; McDonnell G; Hawkins S
Mult Scler; 2009 Jan; 15(1):75-80. PubMed ID: 18829636
[TBL] [Abstract][Full Text] [Related]
73. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
[TBL] [Abstract][Full Text] [Related]
74. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
75. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
Vercellino M; Romagnolo A; Mattioda A; Masera S; Piacentino C; Merola A; Chiò A; Mutani R; Cavalla P
Acta Neurol Scand; 2009 Feb; 119(2):126-30. PubMed ID: 18684216
[TBL] [Abstract][Full Text] [Related]
76. How similar are commonly combined criteria for EDSS progression in multiple sclerosis?
Kragt JJ; Nielsen IM; van der Linden FA; Uitdehaag BM; Polman CH
Mult Scler; 2006 Dec; 12(6):782-6. PubMed ID: 17263007
[TBL] [Abstract][Full Text] [Related]
77. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis.
Bellmann-Strobl J; Wuerfel J; Aktas O; Dörr J; Wernecke KD; Zipp F; Paul F
Neurology; 2009 Nov; 73(20):1624-7. PubMed ID: 19917984
[TBL] [Abstract][Full Text] [Related]
78. A study validating changes in the multiple sclerosis functional composite.
Hoogervorst EL; Kalkers NF; Uitdehaag BM; Polman CH
Arch Neurol; 2002 Jan; 59(1):113-6. PubMed ID: 11790238
[TBL] [Abstract][Full Text] [Related]
79. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
80. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis.
Shevchenko YL; Novik AA; Kuznetsov AN; Afanasiev BV; Lisukov IA; Kozlov VA; Rykavicin OA; Ionova TI; Melnichenko VY; Fedorenko DA; Kulagin AD; Shamanski SV; Ivanov RA; Gorodokin G
Exp Hematol; 2008 Aug; 36(8):922-8. PubMed ID: 18468768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
